May 30, 2017 12:32 pm UTC| Business
NEW YORK and CLEVELAND, May 30, 2017 -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced...
May 30, 2017 12:32 pm UTC| Business
NEW YORK and CLEVELAND, May 30, 2017 -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced...
May 30, 2017 12:32 pm UTC| Business
NEW YORK and CLEVELAND, May 30, 2017 -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced...
May 30, 2017 12:32 pm UTC| Business
NEW YORK and CLEVELAND, May 30, 2017 -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced...
May 30, 2017 12:32 pm UTC| Business
NEW YORK and CLEVELAND, May 30, 2017 -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced...
May 30, 2017 12:32 pm UTC| Business
NEW YORK and CLEVELAND, May 30, 2017 -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced...
May 30, 2017 12:32 pm UTC| Business
NEW YORK and CLEVELAND, May 30, 2017 -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced...